{"database": "openregs", "table": "federal_register", "rows": [["2023-11899", "Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment; Revised Draft Guidance for Industry; Availability", "Notice", "The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled \"Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment.\" This draft guidance is intended to revise and replace the current draft guidance for industry entitled \"Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): Establishing Effectiveness of Drugs for Treatment\" issued on December 5, 2019. This draft guidance provides recommendations for drug development programs for drugs intended to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS).", "2023-06-05", 2023, 6, "https://www.federalregister.gov/documents/2023/06/05/2023-11899/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-for-treatment", "https://www.govinfo.gov/content/pkg/FR-2023-06-05/pdf/2023-11899.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled \"Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment.\" This draft guidance...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2023-11899"], "units": {}, "query_ms": 2.342591993510723, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}